[ad_1]
Vancouver, BC Canada, April 10, 2019 (Ondine Biomedical Inc.) announced today that its Photodisinfection Antimicrobial Therapy (aPDT) has been successfully eradicated by laboratory testing of all multidrug-resistant Candida auris strains. from clinical isolates provided by the Centers for Disease Control and Prevention Research (CDC). This discovery follows the recent acceptance by the 2019 World Congress of the International Photodynamic Association (IPA) of a summary demonstrating the eradication of infection with Aspergillus fumigatus in vivo.
Aspergillus fumigatus, a fungus badociated with invasive fungal sinusitis, is a potentially fatal pathogen for patients with compromised immune systems. Candida auris is an emerging fungus described by the CDC as a "serious global threat to health" because it can cause invasive infections badociated with high mortality rates, it is often resistant to several clbades of antifungal and difficult to identify with standard laboratory methods.
"Demonstrating the effectiveness of this scale against extremely resistant fungal species, both in vitro and in vivo, is a key step in accelerating our antifungal pipeline," said Carolyn Cross, CEO of Ondine. . "We are acutely aware of the need to adopt powerful new approaches in the fight against drug-resistant organisms. As part of the GAIN program, the FDA has recognized the unique drug-device combination of Ondine as a promising treatment for qualified pathogens. The goal of GAIN is to promote the development of new antibacterial and antifungal drugs against pathogens posing a serious threat to public health.
About Candida auris
First identified in 2009 in Japan, C. auris infections have been reported in more than 20 countries worldwide, including the United States. C. auris infections can be invasive and deadly. Often resistant to multiple medications, C. auris is difficult to identify with standard laboratory methods and has been the cause of major epidemics in health facilities. Unlike other Candida species, C. auris is robust and can live on the skin and surfaces, including bed rails and chairs, for a month or more, allowing it to spread easily in nursing homes. Health care. According to the CDC, "most of the strains detected so far were resistant to at least one drug, and more than one-third were resistant to two clbades of drugs.In particular, some strains were resistant to Three clbades of drugs used to treat fungal infections This level of resistance has never been observed in other Candida infections C. auris has a high potential for epidemic in health facilities. "
About photodisinfection
Ondine photodisinfection is a powerful new alternative in the fight against drug-resistant infections. This patented, light-activated antimicrobial removes drug-resistant bacteria, viruses and fungi in minutes, including those found in biofilms. As photodisinfection is effective against such a broad spectrum of pathogens, costly and time-consuming identification of the pathogen is not necessary. Photodisinfection kills microbes by oxidative disruption of the microbial cell membrane without any known adverse effects on human epithelial tissue or mucosa. Microbes are unable to resist or adapt to this treatment.
Ondine photodisinfection is a powerful new alternative in the fight against drug-resistant infections. This patented, light-activated antimicrobial removes drug-resistant bacteria, viruses and fungi in minutes, including those found in biofilms. As photodisinfection is effective against such a broad spectrum of pathogens, costly and time-consuming identification of the pathogen is not necessary. Photodisinfection kills microbes by oxidative disruption of the microbial cell membrane without any known adverse effects on human epithelial tissue or mucosa. Microbes are unable to resist or adapt to this treatment.
Ondine's photodisinfection technology has recently been granted Infectious Disease Product (IDP) status and the FDA's Fast Track status for its nasal decolonization indication for MRSA. The technology has been deployed in major Canadian hospitals for several years, demonstrating a significant and sustained reduction in healthcare-badociated infections as well as major pharmacoeconomic benefits for the hospital and patient.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to developing prevention therapies and therapies for a broad range of multidrug-resistant bacterial, viral and fungal infections. Ondine's antimicrobial program uses a platform technology called Photodisinfection, a light-activated approach under development to provide rapid antimicrobial efficacy without increasing the risk of resistance. In addition to universal treatment with nasal photodisinfection of Ondine, other applications of the photodisinfection platform are under development, including treatment of chronic rhinosinusitis, treatment of burns and wounds and disinfection of endotracheal tubes to reduce incidence of pneumonia badociated with ventilation.
Angelika Vance, Director - Business Development Ondine Biomedical Inc. 6048382702 [email protected]
Source link
